(Información remitida por la empresa firmante)
LUND, Sweden, July 19, 2023 /PRNewswire/ -- Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody ("ANCA")-associated vasculitis.
